Sponsors (5)
The bill aims to lower drug prices and expand competition and transparency by authorizing price findings, compulsory open licensing, and reporting, but does so at the risk of legal complexity, higher administrative costs, and potential reductions in future R&D and timely access to new therapies.
Patients (including those with chronic conditions) and Medicare/Medicaid beneficiaries would pay substantially lower prices for some brand-name drugs because the bill enables findings of 'excessive' U.S. prices, price reductions, and limits on post-finding price increases.
Patients, hospitals, and payers would gain access to more generic and biosimilar suppliers because the law allows open, non‑exclusive licensing and voiding of exclusivity for excessive‑priced drugs, increasing competition and availability.
Patients and health systems could see faster entry of generics and biosimilars because applicants referencing licensed drugs must receive expedited FDA review, shortening time to market.
Drug developers, investors, and ultimately patients could face reduced incentives for R&D and slower development of new therapies because the bill narrows exclusivity, caps returns, and increases the risk of compulsory licensing or price-based penalties.
Patients could lose or face delays in access to new drugs if manufacturers respond by delaying U.S. launches or limiting supplies to avoid increased pricing scrutiny or enforcement.
Manufacturers may pass increased compliance, administrative, or penalty-related costs onto consumers or payers by raising prices for other products or reducing discounting, offsetting some intended savings.
Based on analysis of 8 sections of legislative text.
Introduced May 21, 2025 by Ro Khanna · Last progress May 21, 2025
Requires the Health and Human Services (HHS) Secretary to review brand-name drug prices annually and declare drugs "excessively priced" when U.S. prices exceed median prices in five reference countries or based on other statutory factors. For drugs found excessive, the Secretary can terminate government-granted exclusivities and issue open, non-exclusive licenses so other companies can make generics or biosimilars, subject to reasonable royalties and sale-price limits. The law also creates public reporting requirements, civil penalties for nondisclosure or false reporting, and an HHS database of reviews, petitions, licenses, and related application activity. The bill adds enforcement tools (royalty rules, expedited review timelines for generic/biosimilar applicants, civil suits to recover revenues tied to price increases, and an FTC-style prohibition on anticompetitive conduct) and requires detailed annual manufacturer reporting on prices, sales, R&D, and public subsidies. It directs penalties to NIH research grants and sets timelines for HHS actions (e.g., reviews start within 30 days of enactment; manufacturer reports due annually).